Search Videos and More
News
New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer
Clonal hematopoiesis (CH) is a recently characterized condition in which the genetic mutations associated with leukemia and other blood cancers are found in the blood of individuals without cancer. This pre-cancerous state is fairly common — for example, it’s present in roughly 15% of people over age 65 — but only a small percentage, around 4%, will go on to develop blood cancer.CAR-T-Cell Shows Promise in Patients with Lymphoma of the Brain and Spinal Cord in Early Trial
A CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord, Dana-Farber Cancer Institute investigators report at the 64th American Society of Hematology (ASH) Annual Meeting.
News
Scientists Map Genetic Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome
Every year, up to 1% of patients with chronic lymphocytic leukemia (CLL), a slow-growing blood cancer, have their disease transform into a far more aggressive cancer, a form of lymphoma known as Richter's Syndrome. For the most part, the genomic changes that underlie this metamorphosis and push it forward have been obscure, hindering advances in treatment.
Symposium
San Antonio Breast Cancer Symposium (SABCS): December 2022
The 45th annual San Antonio Breast Cancer Symposium. December 6 - 10, 2022
Document
Breast Oncology Research Presentations Schedule
The 45th annual San Antonio Breast Cancer Symposium. December 6 - 10, 2022
News
Dana-Farber Research Publication 12.1.2021
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber Research Supports FDA Approval of New Therapy for Certain Patients with Ovarian Cancer
A novel antibody drug conjugate therapy whose clinical trial testing has been co-led by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November 14 for the treatment of recurrent platinum-resistant high-grade serous ovarian cancer that highly expresses folate receptor alpha.
News
New International Partnership to Accelerate Search for Cancer Cures
Cancer patients in Australia and the United States will benefit from a new research-focused collaboration between the Peter MacCallum Cancer Centre and Dana-Farber Cancer Institute in Boston.
News
Dana-Farber Cancer Institute Faculty Among World’s Most Highly Cited Researchers
Dana-Farber Cancer Institute is proud to announce that 33 of its researchers have been named to the Highly Cited Researchers list of 2022 released today by the Institute for Scientific Information at Clarivate.
News
Study Shows That Immune System Holds Clues to Patients With High-Risk Smoldering Myeloma Likely to Benefit From Treatment
In a new study, investigators at Dana-Farber Cancer Institute demonstrate that changes in immune system cells can indicate which patients with high-risk "smoldering" myeloma are likely to progress to myeloma and which will benefit the most from treatment.
Document
Treatment Guidelines: Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-low Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on July 1 and July 8, 2022 to discuss recommendations for the use of trastuzumab deruxtecan (T-DXd) in patients with metastatic, HER2-low breast cancer.
Symposium
Research Updates - Metastatic Breast Cancer
In the following videos, faculty from Dana-Farber Cancer Institute review research updates from the 2022-2023 EMBRACE Metastatic Breast Cancer Patient Forum Series.